Biologie et Industrie (B&I), an oncology focussed CRO based in Paris, France, has been acquired by Veeda Oncology, a clinical research organization (CRO). The price was not disclosed. Veeda Oncology, which has operations in India, Eastern Europe, Western Europe and the U.S., offers full service oncology for Phase I through Phase IV. Veeda’s capabilities within Europe will be enhanced by this acquisition of B&I, said Binoy Gardi, co-managing director of the Veeda Group. “The clients of B&I can now access the global oncology patient accrual ability that currently exists within Veeda Oncology as well as the other full service capabilities,” he added. B&I physicians—Rémy Brossel and Sylvie Brossel—will continue working with the company to lead the European operations. Here’s the article.

Chiltern opened a new office in Lisbon, Portugal. Ricardo Diaz will head Chiltern’s new office as country manager. In addition to supporting its own trials, the office will provide personnel, letting local sponsors use Chiltern staff at either clinical sites or at the sponsors’ offices. Such arrangements can be short or long-term. “In the past 2 years, we have seen rising interest in the region and increased demand for full clinical operations support in Portugal,” said Diaz. Here’s the press release.

“In-Sourcing Innovative Products from Asia and South America” is a new session that will be conducted by Amarex Clinical Research at BIO 2008 on June 18 in San Diego, CA. Mukesh Kumar, senior director, Amarex Center will chair this session. Marie Freire, director, Thywill, Argentina, and Keith Chan, president/CEO, GloboAsia, are some of the other speakers at the session. In-sourcing products is an overlooked opportunity in the medical products industry. According to Dr. Kumar “Asia and South America are traditionally viewed as destinations for outsourcing clinical products. Often overlooked is the robust infrastructure in these regions for innovative drug discoveries, particularly for natural products. For a variety of reasons, product transfers from these regions to western markets has been hindered.” Here’s the press release.

Parexel will present at the Robert W. Baird 2008 Growth Stock Conference in Chicago, Illinois. James Winschel, senior VP and CFO will be making a formal presentation on Parexelat at 10:05 a.m. EDT on Thursday, May 15, 2008. A live webcast of this presentation will be available through the “Investor Relations Webcasts” section of Parexel’s website and a replay of the presentation will be available until August 15, 2008.

Nextrials said revenues were up 80 percent in 2007. The privately held company did not disclose any financial data, but said that during the year more than 24 sponsors started trials on its electronic data capture system, called Prism. One customer, Ekos, is a medical device manufacturer. Said Robin Carlson, Ekos’ director of clinical affairs: “We found we were able to quickly use Prism in trials validating our ultrasound-accelerated infusion catheters, and as a result, were able to review patient data in real-time.  This helped our product development team to better understand clinical parameters and ensured the safety of patients enrolled in our studies.” Here’s the release.

Ovation Pharmaceuticals selected DSG’s electronic data capture system for Phase I trials. Five such studies are complete; seven more are underway or planned for 2008; and six additional trials are planned for 2009. The company says the DSG software “is very intuitive and user-friendly, and provides exceptionally clean data, as well as real-time data and monitoring. This translated directly into significant time and cost-savings for us,” said Robert Anders, VP of Ovation’s clinical operations. Here’s the release.

Have a news release? Send it to .